Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Acq. announced
Quarterly results
Consulting agrmnt
CC transcript
|
|
LABORATORY CORP OF AMERICA HOLDINGS (LH)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/07/2023 |
8-K/A
| Financial Statements and Exhibits Interactive Data |
| 05/05/2023 |
8-K/A
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/05/2023 |
8-K/A
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/31/2021 |
8-K/A
| Quarterly results |
| 03/03/2021 |
8-K/A
| Quarterly results |
| 07/26/2019 |
8-K/A
| Quarterly results |
| 10/24/2018 |
8-K/A
| Quarterly results |
| 05/08/2015 |
8-K/A
| Financial Statements and Exhibits|
Docs:
|
"Consent of Independent Auditors",
"LABCORP COMPLETES ACQUISITION OF COVANCE Combination Creates Leading Healthcare Diagnostics Company & End-to-End Solutions for Drug Development and Commercialization",
"Consolidated Financial Statements of Covance Inc. and Subsidiaries at December 31, 2014 and 2013 and for the years ended December 31, 2014, 2013 and 2012",
"UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS The following unaudited pro forma condensed combined financial information has been prepared to illustrate the effect of the following items: Laboratory Corporation of America Holdings acquisition of Covance Inc. , the issuance of an aggregate of $2,900.0 of Senior Unsecured Notes, and the incurrence of $1,000.0 of indebtedness under the Term Loan Facility. Under the terms of the Merger Agreement, each outstanding share of Covance common stock was exchanged for $75.76 in cash, without interest , and 0.2686 of a share of LabCorp common stock . Cash Consideration and Stock Consideration is collectively referred to as the “Merger Consideration.” The following unaudited pro forma condensed combined financial statements give effect to ..." |
|
| 05/07/2015 |
8-K/A
| Financial Statements and Exhibits|
Docs:
|
"Consent of Independent Auditors",
"LABCORP COMPLETES ACQUISITION OF COVANCE Combination Creates Leading Healthcare Diagnostics Company & End-to-End Solutions for Drug Development and Commercialization",
"Consolidated Financial Statements of Covance Inc. and Subsidiaries at December 31, 2014 and 2013 and for the years ended December 31, 2014, 2013 and 2012",
"UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS The following unaudited pro forma condensed combined financial information has been prepared to illustrate the effect of the following items: Laboratory Corporation of America Holdings acquisition of Covance Inc. , the issuance of an aggregate of $2,900.0 of Senior Unsecured Notes, and the incurrence of $1,000.0 of indebtedness under the Term Loan Facility. Under the terms of the Merger Agreement, each outstanding share of Covance common stock was exchanged for $75.76 in cash, without interest , and 0.2686 of a share of LabCorp common stock . Cash Consideration and Stock Consideration is collectively referred to as the “Merger Consideration.” The following unaudited pro forma condensed combined financial statements give effect to ..." |
|
| 05/13/2009 |
8-K/A
| Form 8-K/A - Current report [Amend] |
| 04/23/2009 |
8-K/A
| Form 8-K/A - Current report [Amend] |
| 01/25/2008 |
8-K/A
| Form 8-K/A - Current report [Amend] |
| 10/24/2006 |
8-K/A
| Form 8-K/A - Current report [Amend] |
| 12/01/2005 |
8-K/A
| Form 8-K/A - Current report [Amend] |
| 10/21/2004 |
8-K/A
| Form 8-K/A - Current report [Amend] |
| 02/24/2004 |
8-K/A
| Form 8-K/A - Current report [Amend] |
| 07/08/2003 |
8-K/A
| Form 8-K/A - Current report [Amend] |
| 02/24/2003 |
8-K/A
| Form 8-K/A - Current report [Amend] |
| 02/19/2003 |
8-K/A
| Form 8-K/A - Current report [Amend] |
| 05/09/2002 |
8-K/A
| Form 8-K/A - Current report [Amend] |
| 04/23/2002 |
8-K/A
| Form 8-K/A - Current report [Amend] |
| 03/06/2002 |
8-K/A
| Form 8-K/A - Current report [Amend] |
| 06/07/2000 |
8-K/A
| Form 8-K/A - Current report [Amend] |
| 02/26/1997 |
8-K/A
| Form 8-K/A - Current report [Amend] |
|
|